What does CUSIP 92859E108 represent in this 13F holders report?

CUSIP 92859E108 is the security identifier for VVOS - VIVOS THERAPEUTICS INC - COM used to aggregate holder disclosures.

How many institutions held VVOS - VIVOS THERAPEUTICS INC - COM in Q2 2023?

28 institutional investors reported VVOS - VIVOS THERAPEUTICS INC - COM for Q2 2023. Use the holders table for investor-level position and value details.

VIVOS THERAPEUTICS INC - COM (VVOS)

CUSIP: 92859E108

Q2 2023 13F Holders as of 30 Jun 2023

Security type / class: Equity / COM
Total 13F shares: 4,690,904
Total 13F value: $2,390,698
Share change: -321,410
Put/Call ratio: 0%
SEC-reported price per share: $0.51
Number of holders: 28
Value change: -$123,027
Number of buys: 9
Number of sells: 13

Security key

92859E108

Report period

Q2 2023

Institutions

Top holders

VVOS full security history Ownership snapshot Full 13F holder table Vivos Therapeutics, Inc. SEC filings Vivos Therapeutics, Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of VVOS - VIVOS THERAPEUTICS INC - COM (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

Gurdev Dave Singh

Disclosed value leader

Gurdev Dave Singh

Comparable rows

0/15

Latest evidence

31 Mar 2023

3/4/5 13F Highest disclosed value: $1,728,844 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

Gurdev Dave Singh has the largest disclosed position value at $1.73M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Gurdev Dave Singh's linked filing trail.

Disclosed position value Top 5

Gurdev Dave Singh $1.73M

Strategic Wealth Investment Group... $1.1M

VANGUARD GROUP INC $245.3K

GEODE CAPITAL MANAGEMENT, LLC $68.9K

BARD ASSOCIATES INC $68.8K

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
Gurdev Dave Singh	3/4/5 Chief Medical Officer, Director, 10%+ Owner 3/4/5	— mixed-class rows	$1,728,844 3,266,372 shares mixed-class rows	—	05 Aug 2021
Strategic Wealth Investment Group, LLC	13F Company 13F	— denominator unverified	$1,098,241 3,219,705 shares	—	31 Mar 2023
VANGUARD GROUP INC	13F Company 13F	— denominator unverified	$245,308 719,167 shares	—	31 Mar 2023
GEODE CAPITAL MANAGEMENT, LLC	13F Company 13F	— denominator unverified	$68,882 201,941 shares	—	31 Mar 2023
BARD ASSOCIATES INC	13F Company 13F	— denominator unverified	$68,802 201,704 shares	—	31 Mar 2023
GODSEY & GIBB, INC	13F Company 13F	— denominator unverified	$31,722 92,999 shares	—	31 Mar 2023

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2023

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions

4,690,904

Rows available

Investor	Option	Weight %	Change %	SEC-reported value	* Price	Shares	Share Change	Activity	Report Period

^* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q2 2023 vs Q1 2023 Across Filers

Q1 2023 holders

Q2 2023 holders

Holder diff

Investor	Q1 2023 Shares	Q2 2023 Shares	Share Diff	Share Chg %	Q1 2023 value	Q2 2023 value	Value change	Value Chg %